Moody National Bank Trust Division’s Neurocrine Biosciences NBIX Stock Holding History

Moody National Bank Trust Division’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$873K	Buy	+6,156	New	+$990K	0.07%	262

Other funds holding NBIX

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return

Red Spruce Capital Berwyn, Pennsylvania $283M AUM 29.49% 1-Year Est. Return

Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Private Client Services Louisville, Kentucky $372M AUM 17.65% 1-Year Est. Return

City Center Advisors LLC Troy, Michigan $131M AUM 24.02% 1-Year Est. Return

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return

Moody National Bank Trust Division's NBIX Position: Q3 2026 in Review

Moody National Bank Trust Division opened a new position in Neurocrine Biosciences (NBIX) in Q3 2026: 6,156 shares worth $873K. The stake represents 0.07% of the portfolio and ranks #262 among its holdings.

21 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

Moody National Bank Trust Division held 6,156 shares of Neurocrine Biosciences worth $873K as of Q3 2026.
Neurocrine Biosciences was a new Moody National Bank Trust Division position in Q3 2026.
Neurocrine Biosciences made up 0.07% of Moody National Bank Trust Division's portfolio in Q3 2026, its #262 holding.
21 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Moody National Bank Trust Division's 13F filing for Q3 2026, filed 6 Oct 2026.